clinical trial – Medxy AI

Rilzabrutinib in Moderate-to-Severe Atopic Dermatitis: Assessing Efficacy and Safety in a Phase II Trial

By MedXY 10/28/2025

A phase II trial evaluating rilzabrutinib, a BTK inhibitor, in moderate-to-severe atopic dermatitis showed no significant improvement in primary endpoints but demonstrated rapid itch relief and a favorable safety profile.

Cardiology news Respiratory

Early Intervention in Pulmonary Arterial Hypertension: The Promise of Sotatercept in the First Year Post-Diagnosis

By MedXY 10/25/2025

This article reviews a phase 3 trial analyzing sotatercept's efficacy and safety in newly diagnosed pulmonary arterial hypertension patients, highlighting its potential to reduce clinical worsening early in the disease course.

news Oncology

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

By MedXY 10/25/2025

The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.

Internal Medicine news Rheumatology

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial

By MedXY 10/25/2025

This article reviews a pivotal phase 3 trial demonstrating telitacicept's efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.

Oncology Otorhinolaryngology

Evaluating Atezolizumab Maintenance Therapy in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Insights from the IMvoke010 Trial

By MedXY 10/25/2025

Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting.

Oncology

Cutting-Edge Treatment for EGFR-Mutated NSCLC: Sacituzumab Tirumotecan Shows Promising Survival Benefits

By MedXY 10/25/2025

A phase 3 trial demonstrates that sacituzumab tirumotecan significantly improves progression-free and overall survival in EGFR-mutated advanced NSCLC resistant to TKI therapy.

Oncology Urology

Breakthrough ADC-Based Combination Therapy Achieves Over 95% Disease Control in Advanced Urothelial Cancer

By MedXY 10/24/2025

Datroway combined with rilvegostomig demonstrates impressive tumor response and disease control in advanced urothelial carcinoma, heralding a new therapeutic option in first- and second-line settings.

news

新诊断的儿童免疫性血小板减少症中使用艾曲波帕：早期治疗策略的突破

By MedXY 10/24/2025

这项随机试验表明，艾曲波帕显著改善了新诊断为ITP的儿童的持续血小板反应，提供了一种潜在的早期干预选择。

Hematology-Oncology news Pediatrics

Eltrombopag in Newly Diagnosed Pediatric Immune Thrombocytopenia: A Breakthrough in Early Treatment Strategy

By MedXY 10/24/2025

This randomized trial demonstrates that eltrombopag significantly improves sustained platelet response in children with newly diagnosed ITP, offering a potential early intervention option.

Neurology Specialties

Oral Valiltramiprosate in APOEε4/ε4 Carriers with Early Alzheimer’s Disease: Insights from the Phase III APOLLOE4 Trial

By MedXY 10/21/2025

This phase III trial evaluated oral valiltramiprosate in APOEε4/ε4 homozygotes with early Alzheimer's, showing brain atrophy slowing but limited overall clinical benefit, with nominal improvements in mild cognitive impairment subgroups.

Diabetes & Endocrinology Specialties

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

By MedXY 10/18/2025

The STEP UP trial demonstrates that once-weekly semaglutide 7.2 mg significantly improves weight loss outcomes versus 2.4 mg and placebo in adults with obesity, with a manageable safety profile.

Diabetes & Endocrinology Internal Medicine Specialties

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review

By MedXY 10/18/2025

This phase 2a trial demonstrates that monlunabant induces significant weight loss across various doses in obese adults with metabolic syndrome, with dose-dependent adverse events highlighting the need for further safety evaluation.

Nephrology news Oncology

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib

By MedXY 10/16/2025

This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.

Diabetes & Endocrinology Ophthalmology Specialties

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial

By MedXY 10/15/2025

The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.

Anesthesiology Critical Care news

Individualized Perioperative Blood Pressure Management in Major Abdominal Surgery: Insights from the IMPROVE-multi Trial

By MedXY 10/13/2025

The IMPROVE-multi randomized clinical trial found that tailoring perioperative blood pressure targets to individual preoperative nighttime MAP levels did not reduce postoperative organ injury or mortality compared to routine management in high-risk major abdominal surgery patients.

Neurology news

Simvastatin Fails to Slow Disability Progression in Secondary Progressive Multiple Sclerosis: Insights from the Phase 3 MS-STAT2 Trial

By MedXY 10/10/2025

In a large phase 3 trial, simvastatin 80 mg daily did not reduce disability progression in secondary progressive multiple sclerosis, challenging prior phase 2 results and underscoring the complexity of neurodegeneration in SPMS.

Gastroenterology Internal Medicine

Simplifying Ulcerative Colitis Treatment: Evaluating a Single 1600 mg 5-ASA Tablet Regimen in the EASI Trial

By MedXY 10/09/2025

The EASI trial compared a once-daily 1600 mg 5-ASA tablet with the conventional three 800 mg tablet regimen for ulcerative colitis, finding similar adherence and relapse rates, suggesting a feasible simpler alternative.

Clinical Updates news Oncology Specialties

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial

By MedXY 10/01/2025

A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.

Diabetes & Endocrinology news Specialties

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

By MedXY 09/27/2025

Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies.

Clinical Updates Neurology news

Long-Term Safety and Effectiveness of Personalized Adaptive Deep Brain Stimulation in Parkinson’s Disease

By MedXY 09/26/2025

This international trial demonstrates that personalized adaptive deep brain stimulation (aDBS) is a safe, effective, and well-tolerated long-term therapy for Parkinson's disease patients previously stable on continuous DBS.